Derek DiRocco - 18 May 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: Director
Issuer ticker: ACRV
Reported as of: 18 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 May 2026, 16:33:47 UTC
Prior SEC filing: 20 Feb 2026
Next SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam D. Levy, Attorney-in-Fact

Key filing fact

Derek DiRocco filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 20 May 2026.

Key facts

This page summarizes Derek DiRocco's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 May 2026, 16:33.

Change

Previous filing in this sequence was filed on 20 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001792061 Primary reporting owner

DiRocco Derek

Relationship: Director
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact
Signature date: 20 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRV transaction

Common Stock

Award

Transaction value
Shares: +9,366
Change %
Price: $0.000000^*
Shares after: 9,366
Date: 18 May 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the RSUs for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any stock received upon settlement of the RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the RSUs and underlying common stock.